This dashboard provides comprehensive statistics and analytics for therapeutic ideas in NeuroWiki's invention lab. Ideas represent novel therapeutic concepts built from mechanistic evidence for neurodegenerative diseases.
| Metric | Value |
|---|---|
| Total Idea Pages | 103[1] |
| Ranked Ideas | 25[1:1] |
| Unranked/Placeholder | 78 |
| AD-Focused Ideas | 68[1:2] |
| PD-Focused Ideas | 62[1:3] |
| ALS-Focused Ideas | 45 |
| FTD-Focused Ideas | 38 |
Mechanisms targeting specific proteins or pathways:
| Category | Count | Examples |
|---|---|---|
| Alpha-synuclein targeting | 12 | Payload: Alpha-synuclein RNAi |
| Tau targeting | 8 | Tau PROTAC degrader |
| Neuroinflammation | 15 | NLRP3 inhibitor |
| Mitochondrial function | 9 | SARM1 inhibitor |
| Protein clearance | 11 | HDAC6 agonist |
| Modality | Count |
|---|---|
| Small molecule | 42 |
| Antibody/Protein | 28 |
| Gene therapy | 18 |
| Cell therapy | 8 |
| Combination therapy | 7 |
Based on the 10-dimension rubric (Novelty, Mechanistic Rationale, Root-Cause Coverage, Delivery Feasibility, Safety Plausibility, Combinability, Biomarker Availability, De-risking Path, Multi-disease Potential, Patient Impact):
| Rank | Idea | Score | Key Mechanism |
|---|---|---|---|
| 1 | SIRT1 + NAD+ Combination | 85 | Epigenetic-metabolic |
| 2 | C9orf72 RNA Targeting | 84 | RNA silencing |
| 3 | NfL-Guided Neuroprotection | 84 | Biomarker-driven |
| 4 | Insulin + GLP-1 Combo | 82 | Metabolic modulation |
| 5 | Microglia State Editing | 82 | Cell state modulation |
68 ideas targeting amyloid, tau, neuroinflammation, synaptic loss, and metabolic dysfunction.
62 ideas focused on alpha-synuclein, LRRK2, GBA1, mitophagy, and dopamine neurons.
45 ideas targeting SOD1, C9orf72, TDP-43, and neuroprotection.
38 ideas for tau, progranulin, and TDP-43 pathology.
| Score Range | Ideas |
|---|---|
| 8-10 (Highly Novel) | 22 |
| 5-7 (Moderately Novel) | 48 |
| 2-4 (Incremental) | 33 |
| Approach | Feasibility |
|---|---|
| Peripheral delivery | High |
| AAV gene therapy | Moderate |
| Brain-penetrant small molecules | High |
| Antibody (peripheral) | Moderate |
| Intranasal | High |
Last updated: 2026-03-17